TY - JOUR
T1 - A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery.
AU - Shadbad, Mahdi Abdoli
AU - Asadzadeh, Zahra
AU - Derakhshani, Afshin
AU - Hosseinkhani, Negar
AU - Mokhtarzadeh, Ahad
AU - Baghbanzadeh, Amir
AU - Hajiasgharzadeh, Khalil
AU - Brunetti, Oronzo
AU - Argentiero, Antonella
AU - Racanelli, Vito
AU - Silvestris, Nicola
AU - Baradaran, Behzad
N1 - Funding Information:
We appreciate the researchers of the Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Publisher Copyright:
© 2021
PY - 2021/11
Y1 - 2021/11
N2 - Tumoral programmed cell death ligand 1 (PD-L1) has been implicated in the immune evasion and development of colorectal cancer. Although monoclonal immune checkpoint inhibitors can exclusively improve the prognosis of patients with microsatellite instability-high (MSI-H) and tumor mutational burden-high (TMB-H) colorectal cancer, specific tumor-suppressive microRNAs (miRs) can regulate multiple oncogenic pathways and inhibit the de novo expression of oncoproteins, like PD-L1, both in microsatellite stable (MSS) and MSI-H colorectal cancer cells. This scoping review aimed to discuss the currently available evidence regarding the therapeutic potentiality of PD-L1-inhibiting miRs for colorectal cancer. For this purpose, the Web of Science, Scopus, and PubMed databases were systematically searched to obtain peer-reviewed studies published before 17 March 2021. We have found that miR-191–5p, miR-382–3p, miR-148a-3p, miR‐93–5p, miR-200a-3p, miR-200c-3p, miR-138–5p, miR-140–3p, and miR-15b-5p can inhibit tumoral PD-L1 in colorectal cancer cells. Besides inhibiting PD-L1, miR-140–3p, miR-382–3p, miR-148a-3p, miR‐93–5p, miR-200a-3p, miR-200c-3p, miR-138–5p, and miR-15b-5p can substantially reduce tumor migration, inhibit tumor development, stimulate anti-tumoral immune responses, decrease tumor viability, and enhance the chemosensitivity of colorectal cancer cells regardless of the microsatellite state. Concerning the specific, effective, and safe delivery of these miRs, the single-cell sequencing-guided biocompatible-based delivery of these miRs can increase the specificity of miR delivery, decrease the toxicity of traditional nanoparticles, transform the immunosuppressive tumor microenvironment into the proinflammatory one, suppress tumor development, decrease tumor migration, and enhance the chemosensitivity of tumoral cells regardless of the microsatellite state.
AB - Tumoral programmed cell death ligand 1 (PD-L1) has been implicated in the immune evasion and development of colorectal cancer. Although monoclonal immune checkpoint inhibitors can exclusively improve the prognosis of patients with microsatellite instability-high (MSI-H) and tumor mutational burden-high (TMB-H) colorectal cancer, specific tumor-suppressive microRNAs (miRs) can regulate multiple oncogenic pathways and inhibit the de novo expression of oncoproteins, like PD-L1, both in microsatellite stable (MSS) and MSI-H colorectal cancer cells. This scoping review aimed to discuss the currently available evidence regarding the therapeutic potentiality of PD-L1-inhibiting miRs for colorectal cancer. For this purpose, the Web of Science, Scopus, and PubMed databases were systematically searched to obtain peer-reviewed studies published before 17 March 2021. We have found that miR-191–5p, miR-382–3p, miR-148a-3p, miR‐93–5p, miR-200a-3p, miR-200c-3p, miR-138–5p, miR-140–3p, and miR-15b-5p can inhibit tumoral PD-L1 in colorectal cancer cells. Besides inhibiting PD-L1, miR-140–3p, miR-382–3p, miR-148a-3p, miR‐93–5p, miR-200a-3p, miR-200c-3p, miR-138–5p, and miR-15b-5p can substantially reduce tumor migration, inhibit tumor development, stimulate anti-tumoral immune responses, decrease tumor viability, and enhance the chemosensitivity of colorectal cancer cells regardless of the microsatellite state. Concerning the specific, effective, and safe delivery of these miRs, the single-cell sequencing-guided biocompatible-based delivery of these miRs can increase the specificity of miR delivery, decrease the toxicity of traditional nanoparticles, transform the immunosuppressive tumor microenvironment into the proinflammatory one, suppress tumor development, decrease tumor migration, and enhance the chemosensitivity of tumoral cells regardless of the microsatellite state.
KW - Biocompatible carriers
KW - Colorectal cancer
KW - MicroRNAs
KW - PD-L1
KW - Personalized medicine
KW - Single-cell sequencing
UR - http://www.scopus.com/inward/record.url?scp=85115765037&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115765037&partnerID=8YFLogxK
U2 - 10.1016/j.biopha.2021.112213
DO - 10.1016/j.biopha.2021.112213
M3 - Review article
AN - SCOPUS:85115765037
SN - 0753-3322
VL - 143
JO - Biomedicine and Pharmacotherapy
JF - Biomedicine and Pharmacotherapy
M1 - 112213
ER -